Adma Biologics (ADMA) closed at $9.23 in the latest trading session, marking a -1.7% move from the prior day. This change lagged the S&P 500's daily gain of 0.86%. Meanwhile, the Dow experienced a rise of 0.98%, and the technology-dominated Nasdaq saw an increase of 0.96%.
The stock of infectious disease drug developer has fallen by 0.21% in the past month, leading the Medical sector's loss of 2.34% and the S&P 500's loss of 1.96%.
The investment community will be closely monitoring the performance of Adma Biologics in its forthcoming earnings report. The company's upcoming EPS is projected at $0.19, signifying a 18.75% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $139.8 million, indicating a 4.16% growth compared to the corresponding quarter of the prior year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.78 per share and revenue of $536.82 million, indicating changes of +30% and +5.22%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Adma Biologics is currently exchanging hands at a Forward P/E ratio of 12.09. This indicates a discount in contrast to its industry's Forward P/E of 20.3.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 167, positioning it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
